The differences of the impact of a lipid and protein corona on the colloidal stability, toxicity, and degradation behavior of iron oxide nanoparticles.


Journal

Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249

Informations de publication

Date de publication:
27 May 2021
Historique:
pubmed: 19 5 2021
medline: 1 6 2021
entrez: 18 5 2021
Statut: ppublish

Résumé

In this study, the influence of a serum albumin (SA) and human plasma (HP) derived protein- and lipid molecule corona on the toxicity and biodegradability of different iron oxide nanoparticles (IONP) was investigated. IONP were synthesized and physicochemically characterized regarding size, charge, and colloidal stability. The adsorbed proteins were quantified and separated by gel electrophoresis. Adsorbed lipids were profiled by ultraperformance liquid chromatography-ESI-tandem mass spectrometry. The biocompatibility was investigated using isolated erythrocytes and a shell-less hen's egg model. The biodegradability was assessed by iron release studies in artificial body fluids. The adsorption patterns of proteins and lipids varied depending on the surface characteristics of the IONP like charge and hydrophobicity. The biomolecule corona modified IONP displayed favorable colloidal stability and toxicological profile compared to IONP without biomolecule coronas, reducing erythrocyte aggregation and hemolysis in vitro as well as the corresponding effects ex ovo/in vivo. The coronas decreased the degradation speed of all tested IONP compared to bare particles, but, whereas all IONP degraded at the same rate for the SA corona, substantial differences were evident for IONP with HP-derived corona depending on the lipid adsorption profile. In this study the impact of the proteins and lipids in the biomolecule corona on the entire IONP application cycle from the injection process to the degradation was demonstrated.

Identifiants

pubmed: 34002735
doi: 10.1039/d0nr09053k
doi:

Substances chimiques

Lipids 0
Protein Corona 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9415-9435

Auteurs

Martin Rabel (M)

Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Lessingstraße 8, 07743 Jena, Germany.

Paul Warncke (P)

Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Lessingstraße 8, 07743 Jena, Germany.

Maria Thürmer (M)

Department of Pharmaceutical and Medical Chemistry, Friedrich-Schiller-University Jena, Philosophenweg 14, 07743 Jena, Germany.

Cordula Grüttner (C)

micromod Partikeltechnologie GmbH, Friedrich-Barnewitz-Straße 4, 18119 Rostock, Germany.

Christian Bergemann (C)

chemicell GmbH, Eresburgstraße 22-23, 12103 Berlin, Germany.

Heinz-Dieter Kurland (HD)

Otto Schott Institute of Materials Research (OSIM), Friedrich-Schiller-University Jena, Löbdergraben 32, 07743 Jena, Germany.

Frank A Müller (FA)

Otto Schott Institute of Materials Research (OSIM), Friedrich-Schiller-University Jena, Löbdergraben 32, 07743 Jena, Germany.

Andreas Koeberle (A)

Department of Pharmaceutical and Medical Chemistry, Friedrich-Schiller-University Jena, Philosophenweg 14, 07743 Jena, Germany and Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Mitterweg 24, 6020 Innsbruck, Austria.

Dagmar Fischer (D)

Department of Chemistry and Pharmacy, Friedrich-Alexander-University Erlangen-Nuremberg, Cauerstraße 6, 91058 Erlangen, Germany. dagmar.fischer@fau.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH